Literature DB >> 21859272

Lipids in cystic fibrosis.

Katrin Anne Becker1, Brian Henry, Regan Ziobro, Joachim Riethmüller, Erich Gulbins.   

Abstract

Cystic fibrosis is characterized by severe intestinal and pulmonary symptoms, but also changes in the liver, pancreas and reproductive tract. Since gastrointestinal symptoms can be controlled, the quality of live and longevity of cystic fibrosis patients is mainly determined by pulmonary inflammation and chronic pulmonary infections with Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia and Haemophilus influenzae. Recent studies developed novel and exciting concepts regarding the pathogenesis and treatment of cystic fibrosis. In particular, several studies indicated a critical role of death receptors, caveolae proteins, membrane rafts, alterations of the ceramide metabolism with an accumulation of ceramide and a reduction of 15-keto-prostaglandin 2 in cystic fibrosis lungs. These alterations have been found to be critically involved in the pulmonary inflammation and infection susceptibility of cystic fibrosis patients. However, albeit these studies provided novel insights into molecular mechanisms causing inflammation and vulnerability to infection, the details of these processes are still unknown.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859272     DOI: 10.1586/ers.11.36

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  4 in total

1.  A MALDI-MSI Approach to the Characterization of Radiation-Induced Lung Injury and Medical Countermeasure Development.

Authors:  Claire L Carter; Jace W Jones; Kory Barrow; Kaitlyn Kieta; Cheryl Taylor-Howell; Sean Kearney; Cassandra P Smith; Allison Gibbs; Ann M Farese; Thomas J MacVittie; Maureen A Kane
Journal:  Health Phys       Date:  2015-11       Impact factor: 1.316

Review 2.  Sphingolipids in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Jean-Philip Truman; Ashley J Snider; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-09-21

3.  Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease.

Authors:  Robert A Quinn; Yan Wei Lim; Tytus D Mak; Katrine Whiteson; Mike Furlan; Douglas Conrad; Forest Rohwer; Pieter Dorrestein
Journal:  PeerJ       Date:  2016-08-11       Impact factor: 2.984

4.  Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?

Authors:  Emina Halilbasic; Elisabeth Fuerst; Denise Heiden; Lukasz Japtok; Susanne C Diesner; Michael Trauner; Askin Kulu; Peter Jaksch; Konrad Hoetzenecker; Burkhard Kleuser; Lili Kazemi-Shirazi; Eva Untersmayr
Journal:  Nutrients       Date:  2020-03-14       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.